Company intelligence / Profile preview

Axentis

Zurich, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

Axentis was a Swiss clinical-stage biotechnology company focused on developing inhaled liposomal anti-infectives for chronic respiratory infections. The company utilized its proprietary Fluidosome platform to encapsulate antibiotics like tobramycin, aiming to enhance drug penetration into pulmonary biofilms and reduce systemic toxicity. Its lead program was targeted at treating Pseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. In 2013, the company was acquired by Aradigm Corporation to complement their existing inhaled liposomal ciprofloxacin programs.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small moleculeLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Axentis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axentis.

Explore the full profile